The US FDA approved MedRegen’s IND application for a combined phase I/II trial with MRG-001 for targeting COVID-19 patients....
All research and development was conducted and the results were filed for patent protection leading to licensing deals with MedReg...
The MedRegen leadership partnered with a premier CDMO and invested heavily in developing a subcutaneous formulation of MRG-001 and...
MedRegen LLC was founded with the aid of private investors....
The unique potential of MRG-001 was discovered initially in promoting liver regeneration and the induction of liver allograft acce...
